Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy extension study of Bimatoprost SR in open-angle glaucoma or ocular hypertension
MOH_2020-08-30_009274Phase 3Not yet recruiting
- Sponsor
- Allergan
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bimatoprost in open-angle glaucoma (OAG) and ocular hypertension, sponsored by Allergan. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
bimatoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on MOH_2020-08-30_009274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-08-30_009274.